{"schema_version":"secwatch.filing_event.v1","accession":"0001819790-23-000070","form_type":"8-K","ticker":"TARS","cik":"0001819790","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.430190+00:00","generated_at":"2026-06-11T18:52:14.877326+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Tarsus posts Q2 net loss $31.4M, gets FDA nod for XDEMVY, raises $100M","bullets":["Net loss of $31.4M in Q2 2023 vs $5.7M loss in Q2 2022; no license revenue ($15.3M in prior year).","Cash and marketable securities $178.2M at June 30, 2023; gross proceeds of $100M from August 2023 equity offering.","FDA approved XDEMVY (lotilaner ophthalmic solution) 0.25% for Demodex blepharitis on July 24, 2023; launch expected end of August 2023.","Completed enrollment of Galatea Phase 2a trial evaluating TP-04 for Rosacea; topline data expected in 1H 2024.","Recruited 85-person sales force targeting ~15K optometrists/ophthalmologists; deployed by end of August."],"urls":{"canonical":"https://secwatch.observer/filing/0001819790-23-000070","json":"https://secwatch.observer/filing/0001819790-23-000070.json","markdown":"https://secwatch.observer/filing/0001819790-23-000070.md","text":"https://secwatch.observer/filing/0001819790-23-000070.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819790/000181979023000070/0001819790-23-000070-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819790/000181979023000070/tars-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:52:14.877326+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"45e4bbcf357fc25e196ce1c38be770916522737b","claim":"Tarsus Pharmaceuticals, Inc. reported the second quarter ended June 30, 2023 results: net income net loss of $31.4 million.","evidence_excerpt":"Second quarter net loss for 2023 was $31.4 million, compared to a net loss of $5.7 million for the same period in 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979023000070/0001819790-23-000070-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"net loss of $31.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}